FDA approves Travere's sparsentan/sparsentan to treat rare kidney disease IgA nephropathy

The U.S. Food and Drug Administration (FDA) announced full approval of Travere Therapeutics’ Sparsentan (Sparsentan), which is designed to slow the decline in kidney function in adults with primary IgA nephropathy (IgAN). This major approval marks an important development in the field of IgAN treatment and brings new hope to patients.

PrimaryIgA nephropathy is a chronic kidney disease caused by the abnormal accumulation of IgA in the kidneys, affecting up to 150,000 people. The occurrence of this disease can lead to damage to the filtering function of the kidneys, which can lead to a series of health problems. Specifically, when the filtration system of the kidneys is damaged, components in the blood, such as proteins, may leak into the urine, forming proteinuria, which will further aggravate the decline in kidney function and may even lead to the occurrence of end-stage renal disease (ESRD).

Sparsentan, as a new type of therapeutic drug, was first approved through the FDA's accelerated approval pathway in February 2023. It is specially designed for patients with primary IgAN who are at risk of rapid disease progression. It is unique in that it is an oral medication that only needs to be taken once daily and is different from traditional immunosuppressive drugs. Sparsentan can effectively slow down the progression of the disease by blocking two key pathways for IgAN disease progression and directly targeting glomerular damage in the kidneys.

The FDA's recent decision not only expands the indications for sparsentan to include all patients at risk of disease progression. This initiative is supported by positive results from the Phase III PROTECT study. In the study, sparsentan was compared with irbesartan and showed a significant slowing of kidney function decline over two years. According to the study results, sparsentan's therapeutic effect on proteinuria continued after week 36 and into the two-year measurement period, fully demonstrating its good tolerability and safety.

We know that mostIgAN patients are at risk of disease progression, and they urgently seek a safe, effective and convenient treatment option to protect their kidney function. Full approval of sparsentan enables physicians to more broadly offer it as a once-daily oral, non-immunosuppressive treatment that better protects patients' kidney function and replaces the current standard of care.

It is worth noting that one month before Sparsentine was approved,The FDA also approved Novartis' Fabhalta (Iptacopan) as an accelerated treatment option to reduce proteinuria in adult patients with IgAN who are at risk for rapid disease progression. Fabalta, an oral B-factor alternative complement pathway drug, has shown promising efficacy in multiple clinical trials and is approved to treat adults with the rare blood disorder paroxysmal interhemoglobinuria. This demonstrates that the treatment landscape for IgAN is rapidly evolving and patient options are increasing.

Overall, the approval of sparsentan not only providesIgAN patients with an innovative treatment option, but also demonstrates the continuous progress of modern medicine in the treatment of chronic kidney disease. With the emergence of more new drugs, the quality of life and prognosis of IgAN patients are expected to be significantly improved in the future. The promotion of various new treatments will bring new hope to patients, helping them better manage diseases and maintain a healthy life.

References:https://pmlive.com/pharma_news/fda-grants-full-approval-to-traveres-filspari-for-rare-kidney-disease-iga-nephropathy/